Given that HDAC inhibitors increase FOXO1 expression, thereby inhibiting tumor growth, and that silencing FOXO1 dampens this effect, we are tempted to speculate that autophagy and lysosomal biogenesis activated by MiT/TFE and/or FOXH1 may be the pathways of choice for targeted cancer therapy. This evidence concerns the gene FOXO1 and neoplasm.